Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 119 entries
Sorted by: Best Match Show Resources per page
The law and politics of workplace wellness. Editor's note.

Journal of health politics, policy and law

Grogan CM.
PMID: 25436271
J Health Polit Policy Law. 2014 Oct;39(5):955-6.

No abstract available.

Cite
Grogan CM. The law and politics of workplace wellness. Editor's note. J Health Polit Policy Law. 2014;39(5):955-6
Grogan, C. M. (2014). The law and politics of workplace wellness. Editor's note. Journal of health politics, policy and law, 39(5), 955-6.
Grogan, Colleen M. "The law and politics of workplace wellness. Editor's note." Journal of health politics, policy and law vol. 39,5 (2014): 955-6.
Grogan CM. The law and politics of workplace wellness. Editor's note. J Health Polit Policy Law. 2014 Oct;39(5):955-6. PMID: 25436271.
Copy Download .nbib Format: NLM
The orthotic treatment of stable ankle fractures.

Orthopedics

Polakoff DR, Pearce SM, Grogan DP, Burkhead WZ.
PMID: 24822972
Orthopedics. 1984 Nov;7(11):1712-5. doi: 10.3928/0147-7447-19841101-10.

Fifteen limbs with stable lateral malleolar fractures treated with an adjustable, functional orthosis were compared to 12 limbs managed with short leg walking casts. The limbs managed with the adjustable orthosis were clinically healed at an average of 3.3...

Cite
Polakoff DR, Pearce SM, Grogan DP, et al. The orthotic treatment of stable ankle fractures. Orthopedics. 1984;7(11):1712-5doi: 10.3928/0147-7447-19841101-10.
Polakoff, D. R., Pearce, S. M., Grogan, D. P., & Burkhead, W. Z. (1984). The orthotic treatment of stable ankle fractures. Orthopedics, 7(11), 1712-5. https://doi.org/10.3928/0147-7447-19841101-10
Polakoff, D R, et al. "The orthotic treatment of stable ankle fractures." Orthopedics vol. 7,11 (1984): 1712-5. doi: https://doi.org/10.3928/0147-7447-19841101-10
Polakoff DR, Pearce SM, Grogan DP, Burkhead WZ. The orthotic treatment of stable ankle fractures. Orthopedics. 1984 Nov;7(11):1712-5. doi: 10.3928/0147-7447-19841101-10. PMID: 24822972.
Copy Download .nbib Format: NLM
Planarizing technique for ion-beam polishing of diamond films.

Applied optics

Grogan DF, Zhao T, Bovard BG, Macleod HA.
PMID: 20720781
Appl Opt. 1992 Apr 01;31(10):1483-7. doi: 10.1364/AO.31.001483.

Diamond films, deposited on silicon substrates through microwave-assisted chemical vapor deposition, have been polished with a 500-eV beam of oxygen ions through the use of a planarizing layer. The films' surface roughness, in excess of 1 microm (rms) and...

Cite
Grogan DF, Zhao T, Bovard BG, et al. Planarizing technique for ion-beam polishing of diamond films. Appl Opt. 1992;31(10):1483-7doi: 10.1364/AO.31.001483.
Grogan, D. F., Zhao, T., Bovard, B. G., & Macleod, H. A. (1992). Planarizing technique for ion-beam polishing of diamond films. Applied optics, 31(10), 1483-7. https://doi.org/10.1364/AO.31.001483
Grogan, D F, et al. "Planarizing technique for ion-beam polishing of diamond films." Applied optics vol. 31,10 (1992): 1483-7. doi: https://doi.org/10.1364/AO.31.001483
Grogan DF, Zhao T, Bovard BG, Macleod HA. Planarizing technique for ion-beam polishing of diamond films. Appl Opt. 1992 Apr 01;31(10):1483-7. doi: 10.1364/AO.31.001483. PMID: 20720781.
Copy Download .nbib Format: NLM
The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8.

Oncoimmunology

Johnston RJ, Yu X, Grogan JL.
PMID: 26405604
Oncoimmunology. 2015 May 27;4(9):e1036214. doi: 10.1080/2162402X.2015.1036214. eCollection 2015 Sep.

Success in eliciting tumor rejection by therapeutic blockade of T cell checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4, has spurred re-evaluation of additional receptors that regulate antitumor responses. Here we summarize our recent studies characterizing the role of co-inhibitory...

Cite
Johnston RJ, Yu X, Grogan JL. The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8. Oncoimmunology. 2015;4(9):e1036214doi: 10.1080/2162402X.2015.1036214.
Johnston, R. J., Yu, X., & Grogan, J. L. (2015). The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8. Oncoimmunology, 4(9), e1036214. https://doi.org/10.1080/2162402X.2015.1036214
Johnston, Robert J, et al. "The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8." Oncoimmunology vol. 4,9 (2015): e1036214. doi: https://doi.org/10.1080/2162402X.2015.1036214
Johnston RJ, Yu X, Grogan JL. The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8. Oncoimmunology. 2015 May 27;4(9):e1036214. doi: 10.1080/2162402X.2015.1036214. eCollection 2015 Sep. PMID: 26405604; PMCID: PMC4570113.
Copy Download .nbib Format: NLM
ATTR Amyloidosis: Current and Emerging Management Strategies: .

JACC. CardioOncology

Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK.
PMID: 34729521
JACC CardioOncol. 2021 Oct 19;3(4):488-505. doi: 10.1016/j.jaccao.2021.06.006. eCollection 2021 Oct.

Transthyretin cardiac amyloidosis (ATTR-CA) is increasingly diagnosed owing to the emergence of noninvasive imaging and improved awareness. Clinical penetrance of pathogenic alleles is not complete and therefore there is a large cohort of asymptomatic transthyretin variant carriers. Screening strategies,...

Cite
Griffin JM, Rosenthal JL, Grodin JL, et al. ATTR Amyloidosis: Current and Emerging Management Strategies: . JACC CardioOncol. 2021;3(4):488-505doi: 10.1016/j.jaccao.2021.06.006.
Griffin, J. M., Rosenthal, J. L., Grodin, J. L., Maurer, M. S., Grogan, M., & Cheng, R. K. (2021). ATTR Amyloidosis: Current and Emerging Management Strategies: . JACC. CardioOncology, 3(4), 488-505. https://doi.org/10.1016/j.jaccao.2021.06.006
Griffin, Jan M, et al. "ATTR Amyloidosis: Current and Emerging Management Strategies: ." JACC. CardioOncology vol. 3,4 (2021): 488-505. doi: https://doi.org/10.1016/j.jaccao.2021.06.006
Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR Amyloidosis: Current and Emerging Management Strategies: . JACC CardioOncol. 2021 Oct 19;3(4):488-505. doi: 10.1016/j.jaccao.2021.06.006. eCollection 2021 Oct. PMID: 34729521; PMCID: PMC8543085.
Copy Download .nbib Format: NLM
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".

Cancers

Keegan NM, Furney SJ, Walshe JM, Gullo G, Kennedy MJ, Smith D, McCaffrey J, Kelly CM, Egan K, Kerr J, Given M, O'Donovan P, Hernando A, Teiserskiene A, Parker I, Kay E, Farrelly A, Carr A, Calzaferri G, McDermott R, Keane MM, Grogan L, Breathnach O, Morris PG, Toomey S, Hennessy BT.
PMID: 33799597
Cancers (Basel). 2021 Mar 11;13(6). doi: 10.3390/cancers13061225.

BACKGROUND: Activation of the phosphoinositide-3 kinase (PI3K) pathway is a resistance mechanism to anti-human epidermal growth factor receptor 2 (HER2) therapy. This phase Ib trial was conducted to determine the maximum tolerated dose (MTD) of copanlisib, an intravenous (IV)...

Cite
Keegan NM, Furney SJ, Walshe JM, et al. Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER". Cancers (Basel). 2021;13(6)doi: 10.3390/cancers13061225.
Keegan, N. M., Furney, S. J., Walshe, J. M., Gullo, G., Kennedy, M. J., Smith, D., McCaffrey, J., Kelly, C. M., Egan, K., Kerr, J., Given, M., O'Donovan, P., Hernando, A., Teiserskiene, A., Parker, I., Kay, E., Farrelly, A., Carr, A., Calzaferri, G., McDermott, R., Keane, M. M., Grogan, L., Breathnach, O., Morris, P. G., Toomey, S., & Hennessy, B. T. (2021). Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER". Cancers, 13(6), . https://doi.org/10.3390/cancers13061225
Keegan, Niamh M, et al. "Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER"." Cancers vol. 13,6 (2021). doi: https://doi.org/10.3390/cancers13061225
Keegan NM, Furney SJ, Walshe JM, Gullo G, Kennedy MJ, Smith D, McCaffrey J, Kelly CM, Egan K, Kerr J, Given M, O'Donovan P, Hernando A, Teiserskiene A, Parker I, Kay E, Farrelly A, Carr A, Calzaferri G, McDermott R, Keane MM, Grogan L, Breathnach O, Morris PG, Toomey S, Hennessy BT. Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER". Cancers (Basel). 2021 Mar 11;13(6). doi: 10.3390/cancers13061225. PMID: 33799597; PMCID: PMC7999809.
Copy Download .nbib Format: NLM
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.

Nature medicine

Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE, Koeppen H, Chen YJ, Modrusan Z, Grogan JL, Banchereau R, Leng N, Thastrom A, Shen X, Hashimoto K, Tayama D, van der Heijden MS, Rosenberg JE, McDermott DF, Powles T, Hegde PS, Huseni MA, Mariathasan S.
PMID: 33547461
Nat Med. 2021 Mar;27(3):560. doi: 10.1038/s41591-021-01246-4.

No abstract available.

Cite
Yuen KC, Liu LF, Gupta V, et al. Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med. 2021;27(3):560doi: 10.1038/s41591-021-01246-4.
Yuen, K. C., Liu, L. F., Gupta, V., Madireddi, S., Keerthivasan, S., Li, C., Rishipathak, D., Williams, P., Kadel, E. E., Koeppen, H., Chen, Y. J., Modrusan, Z., Grogan, J. L., Banchereau, R., Leng, N., Thastrom, A., Shen, X., Hashimoto, K., Tayama, D., van der Heijden, M. S., Rosenberg, J. E., McDermott, D. F., Powles, T., Hegde, P. S., Huseni, M. A., & Mariathasan, S. (2021). Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nature medicine, 27(3), 560. https://doi.org/10.1038/s41591-021-01246-4
Yuen, Kobe C, et al. "Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade." Nature medicine vol. 27,3 (2021): 560. doi: https://doi.org/10.1038/s41591-021-01246-4
Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE, Koeppen H, Chen YJ, Modrusan Z, Grogan JL, Banchereau R, Leng N, Thastrom A, Shen X, Hashimoto K, Tayama D, van der Heijden MS, Rosenberg JE, McDermott DF, Powles T, Hegde PS, Huseni MA, Mariathasan S. Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med. 2021 Mar;27(3):560. doi: 10.1038/s41591-021-01246-4. PMID: 33547461.
Copy Download .nbib Format: NLM
Anxiolytic, Promnesic, Anti-Acetylcholinesterase and Antioxidant Effects of Cotinine and 6-Hydroxy-L-Nicotine in Scopolamine-Induced Zebrafish (.

Antioxidants (Basel, Switzerland)

Boiangiu RS, Mihasan M, Gorgan DL, Stache BA, Hritcu L.
PMID: 33535660
Antioxidants (Basel). 2021 Feb 01;10(2). doi: 10.3390/antiox10020212.

Cotinine (COT) and 6-hydroxy-L-nicotine (6HLN) are two nicotinic derivatives that possess cognitive-improving abilities and antioxidant properties in different rodent models of Alzheimer's disease (AD), eluding the side-effects of nicotine (NIC), the parent molecule. In the current study, we evaluated...

Cite
Boiangiu RS, Mihasan M, Gorgan DL, et al. Anxiolytic, Promnesic, Anti-Acetylcholinesterase and Antioxidant Effects of Cotinine and 6-Hydroxy-L-Nicotine in Scopolamine-Induced Zebrafish (. Antioxidants (Basel). 2021;10(2)doi: 10.3390/antiox10020212.
Boiangiu, R. S., Mihasan, M., Gorgan, D. L., Stache, B. A., & Hritcu, L. (2021). Anxiolytic, Promnesic, Anti-Acetylcholinesterase and Antioxidant Effects of Cotinine and 6-Hydroxy-L-Nicotine in Scopolamine-Induced Zebrafish (. Antioxidants (Basel, Switzerland), 10(2), . https://doi.org/10.3390/antiox10020212
Boiangiu, Razvan Stefan, et al. "Anxiolytic, Promnesic, Anti-Acetylcholinesterase and Antioxidant Effects of Cotinine and 6-Hydroxy-L-Nicotine in Scopolamine-Induced Zebrafish (." Antioxidants (Basel, Switzerland) vol. 10,2 (2021). doi: https://doi.org/10.3390/antiox10020212
Boiangiu RS, Mihasan M, Gorgan DL, Stache BA, Hritcu L. Anxiolytic, Promnesic, Anti-Acetylcholinesterase and Antioxidant Effects of Cotinine and 6-Hydroxy-L-Nicotine in Scopolamine-Induced Zebrafish (. Antioxidants (Basel). 2021 Feb 01;10(2). doi: 10.3390/antiox10020212. PMID: 33535660; PMCID: PMC7912787.
Copy Download .nbib Format: NLM
Investigation of polyethylene terephthalate (PET) drinking bottles as marine reservoirs for fecal bacteria and phytoplankton.

Marine pollution bulletin

Grogan AE, Mallin MA, Cahoon LB.
PMID: 34872168
Mar Pollut Bull. 2021 Dec;173:113052. doi: 10.1016/j.marpolbul.2021.113052. Epub 2021 Oct 28.

Polyethylene terephthalate (PET) is frequently used in the food and beverage industry and therefore contributes greatly to plastic marine debris. The fecal pollution indicator bacteria Enterococcus is used for marine water contamination assessments and is regularly found in storm...

Cite
Grogan AE, Mallin MA, Cahoon LB. Investigation of polyethylene terephthalate (PET) drinking bottles as marine reservoirs for fecal bacteria and phytoplankton. Mar Pollut Bull. 2021;173:113052doi: 10.1016/j.marpolbul.2021.113052.
Grogan, A. E., Mallin, M. A., & Cahoon, L. B. (2021). Investigation of polyethylene terephthalate (PET) drinking bottles as marine reservoirs for fecal bacteria and phytoplankton. Marine pollution bulletin, 173113052. https://doi.org/10.1016/j.marpolbul.2021.113052
Grogan, Amy E, et al. "Investigation of polyethylene terephthalate (PET) drinking bottles as marine reservoirs for fecal bacteria and phytoplankton." Marine pollution bulletin vol. 173 (2021): 113052. doi: https://doi.org/10.1016/j.marpolbul.2021.113052
Grogan AE, Mallin MA, Cahoon LB. Investigation of polyethylene terephthalate (PET) drinking bottles as marine reservoirs for fecal bacteria and phytoplankton. Mar Pollut Bull. 2021 Dec;173:113052. doi: 10.1016/j.marpolbul.2021.113052. Epub 2021 Oct 28. PMID: 34872168.
Copy Download .nbib Format: NLM
Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population.

Journal of cardiac failure

Kozlitina J, Garg S, Drazner MH, Matulevicius SA, Ayers C, Overton J, Reid J, Baras A, Rao K, Pandey A, Berry J, de Lemos JA, Grodin JL.
PMID: 34634447
J Card Fail. 2021 Oct 09; doi: 10.1016/j.cardfail.2021.09.015. Epub 2021 Oct 09.

BACKGROUND: The V122I variant in transthyretin (TTR) is the most common amyloidogenic mutation worldwide. The aim of this study is to describe the cardiac phenotype and risk for adverse cardiovascular outcomes of young V122I TTR carriers in the general...

Cite
Kozlitina J, Garg S, Drazner MH, et al. Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population. J Card Fail. 2021;doi: 10.1016/j.cardfail.2021.09.015.
Kozlitina, J., Garg, S., Drazner, M. H., Matulevicius, S. A., Ayers, C., Overton, J., Reid, J., Baras, A., Rao, K., Pandey, A., Berry, J., de Lemos, J. A., & Grodin, J. L. (2021). Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population. Journal of cardiac failure, . https://doi.org/10.1016/j.cardfail.2021.09.015
Kozlitina, Julia, et al. "Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population." Journal of cardiac failure vol. (2021). doi: https://doi.org/10.1016/j.cardfail.2021.09.015
Kozlitina J, Garg S, Drazner MH, Matulevicius SA, Ayers C, Overton J, Reid J, Baras A, Rao K, Pandey A, Berry J, de Lemos JA, Grodin JL. Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population. J Card Fail. 2021 Oct 09; doi: 10.1016/j.cardfail.2021.09.015. Epub 2021 Oct 09. PMID: 34634447.
Copy Download .nbib Format: NLM
COVID-19-related mortality in cancer patients in an Irish setting.

Irish journal of medical science

Linehan A, Fitzpatrick O, Cowzer D, Hennessy MA, Coyne ZL, Nolan A, Clarke M, Dhonaill RN, Hennessy BT, Morris PG, Grogan L, Breathnach O.
PMID: 34697787
Ir J Med Sci. 2021 Oct 25; doi: 10.1007/s11845-021-02815-9. Epub 2021 Oct 25.

BACKGROUND: The COVID-19 pandemic has impacted significantly on healthcare across the globe. It has been reported to have higher incidence and be associated with worse outcomes in patients with cancer.AIM: To examine the characteristics of patients with cancer who...

Cite
Linehan A, Fitzpatrick O, Cowzer D, et al. COVID-19-related mortality in cancer patients in an Irish setting. Ir J Med Sci. 2021;doi: 10.1007/s11845-021-02815-9.
Linehan, A., Fitzpatrick, O., Cowzer, D., Hennessy, M. A., Coyne, Z. L., Nolan, A., Clarke, M., Dhonaill, R. N., Hennessy, B. T., Morris, P. G., Grogan, L., & Breathnach, O. (2021). COVID-19-related mortality in cancer patients in an Irish setting. Irish journal of medical science, . https://doi.org/10.1007/s11845-021-02815-9
Linehan, Anna, et al. "COVID-19-related mortality in cancer patients in an Irish setting." Irish journal of medical science vol. (2021). doi: https://doi.org/10.1007/s11845-021-02815-9
Linehan A, Fitzpatrick O, Cowzer D, Hennessy MA, Coyne ZL, Nolan A, Clarke M, Dhonaill RN, Hennessy BT, Morris PG, Grogan L, Breathnach O. COVID-19-related mortality in cancer patients in an Irish setting. Ir J Med Sci. 2021 Oct 25; doi: 10.1007/s11845-021-02815-9. Epub 2021 Oct 25. PMID: 34697787; PMCID: PMC8545357.
Copy Download .nbib Format: NLM
ATTR Amyloidosis: Current and Emerging Management Strategies: .

JACC. CardioOncology

Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK.
PMID: 34729521
JACC CardioOncol. 2021 Oct 19;3(4):488-505. doi: 10.1016/j.jaccao.2021.06.006. eCollection 2021 Oct.

Transthyretin cardiac amyloidosis (ATTR-CA) is increasingly diagnosed owing to the emergence of noninvasive imaging and improved awareness. Clinical penetrance of pathogenic alleles is not complete and therefore there is a large cohort of asymptomatic transthyretin variant carriers. Screening strategies,...

Cite
Griffin JM, Rosenthal JL, Grodin JL, et al. ATTR Amyloidosis: Current and Emerging Management Strategies: . JACC CardioOncol. 2021;3(4):488-505doi: 10.1016/j.jaccao.2021.06.006.
Griffin, J. M., Rosenthal, J. L., Grodin, J. L., Maurer, M. S., Grogan, M., & Cheng, R. K. (2021). ATTR Amyloidosis: Current and Emerging Management Strategies: . JACC. CardioOncology, 3(4), 488-505. https://doi.org/10.1016/j.jaccao.2021.06.006
Griffin, Jan M, et al. "ATTR Amyloidosis: Current and Emerging Management Strategies: ." JACC. CardioOncology vol. 3,4 (2021): 488-505. doi: https://doi.org/10.1016/j.jaccao.2021.06.006
Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR Amyloidosis: Current and Emerging Management Strategies: . JACC CardioOncol. 2021 Oct 19;3(4):488-505. doi: 10.1016/j.jaccao.2021.06.006. eCollection 2021 Oct. PMID: 34729521; PMCID: PMC8543085.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 119 entries